Our products

Learn more about our product portfolio and how we’re prioritising vaccines and specialty medicines to get ahead of disease together.

Scroll to explore

Our product areas

Shingles cell



Our unrivalled vaccine portfolio targets infectious diseases at every stage of life. From adjuvants that improve vaccine effectiveness, through to mRNA technology, we use advanced technologies and collaborate with our partners to develop new, more effective vaccines that help people around the world to get ahead of disease.

COVID virus cell

Specialty medicines

Specialty medicines

As our experts seek innovative new ways to treat the human body, specialty medicines are at the forefront of our high-value pipeline of new products. We are global leaders in developing medicines for respiratory disease and HIV, and we are building our presence in other key therapy areas such as immunology and oncology.

DNA strand graphic

General medicines

General medicines

General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. For us, this includes our medicines for inhaled respiratory, dermatology and other diseases. These vital medications are the engine room of GSK, supporting hundreds of millions of people to enjoy a better everyday quality of life.

Our vaccines and medicines

Getting ahead means preventing disease as well as treating it. Our R&D focus is to deliver new vaccines and medicines using the science of the immune system and advanced technologies to impact health at scale.

vaccines manufacturing sites - enabling a supply capability to produce and deliver 500 million vaccine doses in 2022
doses of vaccines delivered every day
vaccines, helping to protect lives from diseases including meningitis, shingles, flu, whooping cough, measles, hepatitis and human papillomavirus (HPV)
of the world’s children receive a GSK vaccine each year
packs of medicines and doses of vaccines delivered in 2022